公开(公告)号：US11919910B2

公开(公告)日：2024-03-05

申请号：US17983474

申请日：2022-11-09

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Xuechao Xing ,  Yong He ,  Matthew C. Rhodes ,  Yat Sun Or

IPC: C07D487/10 ,  A61P31/14

CPC classification number: C07D487/10 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11834436B2

公开(公告)日：2023-12-05

申请号：US17228815

申请日：2021-04-13

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Brett Granger ,  Jing He ,  Xuechao Xing ,  Yong He ,  Jiang Long ,  Jun Ma ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D413/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14

CPC classification number: C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:




which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

公开(公告)号：US20230143250A1

公开(公告)日：2023-05-11

申请号：US17891436

申请日：2022-08-19

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Jun Ma ,  Brett Granger ,  Jiang Long ,  Bin Wang ,  Sourav Ghorai ,  Jing He ,  Yong He ,  Xuechao Xing ,  Ruichao Shen ,  Yat Sun Or

IPC: C07D265/36 ,  C07D277/36 ,  C07C311/29 ,  C07D217/20 ,  C07D471/04 ,  C07D209/18 ,  C07D209/44 ,  C07D417/12 ,  C07D417/04 ,  C07D307/81

CPC classification number: C07D265/36 ,  C07D277/36 ,  C07C311/29 ,  C07D217/20 ,  C07D471/04 ,  C07D209/18 ,  C07D209/44 ,  C07D417/12 ,  C07D417/04 ,  C07D307/81

Abstract: The present invention provides compounds of Formula (I),




pharmaceutical compositions comprising these compounds and methods of using these compounds to provides a method of modulating a HSD17B13 protein for treatment of metabolic disease or liver condition, The present invention relates generally to compounds and pharmaceutical compositions useful as 17β-HSD13 inhibitors. Specifically, the present invention relates to compounds useful as inhibitors of 17β-HSD13 and methods for their preparation and use.

公开(公告)号：US20230122228A1

公开(公告)日：2023-04-20

申请号：US17720603

申请日：2022-04-14

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Ruichao Shen ,  Yong He ,  Xuechao Xing ,  Matthew C. Rhodes ,  Joseph D. Panarese ,  Samuel Bartlett ,  Wei Li ,  Hui Cao ,  Jiajun Zhang ,  Xiaowen Peng ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D487/10 ,  A61P31/14 ,  A61P11/00 ,  A61K9/00

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20220356167A1

公开(公告)日：2022-11-10

申请号：US17197399

申请日：2021-03-10

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Jiang Long ,  Jun Ma ,  Xuechao Xing ,  Yong He ,  Brett Granger ,  Jing He ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D417/14 ,  C07D413/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US11345699B2

公开(公告)日：2022-05-31

申请号：US16688429

申请日：2019-11-19

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Brett Granger ,  Guoqiang Wang ,  Ruichao Shen ,  Jing He ,  Yong He ,  Xuechao Xing ,  Jun Ma ,  Jiang Long ,  Bin Wang ,  Yat Sun Or

IPC: C07D471/04 ,  C07D401/14 ,  C07D417/14 ,  C07D405/14 ,  C07D413/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US20220119366A1

公开(公告)日：2022-04-21

申请号：US17228815

申请日：2021-04-13

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Brett Granger ,  Jing He ,  Xuechao Xing ,  Yong He ,  Jiang Long ,  Jun Ma ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D413/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

公开(公告)号：US20210238188A1

公开(公告)日：2021-08-05

申请号：US17155159

申请日：2021-01-22

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yong He ,  Xuechao Xing ,  Guoqiang Wang ,  Ruichao Shen ,  Brett Granger ,  Jiang Long ,  Yat Sun Or

IPC: C07D491/048 ,  A61K45/06

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US10988458B2

公开(公告)日：2021-04-27

申请号：US16866778

申请日：2020-05-05

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Jiang Long ,  Jun Ma ,  Xuechao Xing ,  Yong He ,  Brett Granger ,  Jing He ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D405/14 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D403/12

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US20200317717A1

公开(公告)日：2020-10-08

申请号：US16854334

申请日：2020-04-21

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Yong He ,  Brett Granger ,  Xuechao Xing ,  Yat Sun Or

IPC: C07J41/00 ,  C07J43/00

Abstract: The present invention relates to processes for preparing compounds of Formula (I) and Formula (II): These compounds are useful as FXR or TGR5 modulators. The present invention also relates to processes for the preparation of the compounds of Formula (III), Formula (IV), Formula (V), and Formula (VI), The present invention also relates to a process for the preparation of compounds (VII), (VIII) and (IX),